Two people can carry the same change in a gene and have very different experiences. One has frequent fevers and abdominal pain. Another has mild symptoms, or none at all. If the gene is the same, why is the illness different?
Familial Mediterranean fever, or FMF, teaches us an important lesson: genes matter, but a laboratory report does not tell the whole story. Understanding the pattern of illness is just as important.
What the gene helps explain
The MEFV gene provides instructions for pyrin, a protein involved in the innate immune system’s response to danger. Certain changes can make this inflammatory system too easy to activate. That helps explain why someone can develop inflammation without having a new infection each time.
Typical FMF attacks involve fever and inflammation affecting the abdomen, chest, joints, or skin. Many attacks last about one to three days, although a person’s illness may not fit every textbook description. Ancestry and family history can be helpful clues, but FMF is not restricted to a single ethnic group.
What does one variant mean?
FMF is usually inherited in an autosomal recessive pattern, involving disease-causing variants in both copies of MEFV. Yet real clinical situations can be more complicated. Some people with a convincing inflammatory illness have only one variant identified. Most people carrying a single FMF-associated variant do not develop typical FMF.
The exact variant, the symptoms, family history, and the limits of the test all matter. Some changes in the same gene can also cause other pyrin-related inflammatory conditions. A specialist should interpret the result in context; “a variant was found” and “the diagnosis is established” are different statements.
A variant of uncertain significance means the laboratory does not have enough evidence to call that change disease-causing or harmless. It is not a positive diagnosis. Keep the actual report, rather than only a note saying “genetic testing positive.”
Why symptoms differ
Other genes, environmental exposures, and treatment can influence how an illness appears. Studies of people living in different settings have helped researchers explore this variability. Those observations do not establish that moving, changing the microbiome, or following a particular diet will control FMF.
This uncertainty should not become blame. A person with difficult disease has not failed to find the right lifestyle trick. Healthy routines can support well-being, but they do not replace anti-inflammatory treatment when it is needed.
The quiet days count too
Feeling better between attacks is welcome, but symptoms alone may not show whether inflammation is fully controlled. In some people, inflammation continues quietly. Persistently uncontrolled inflammation can lead to AA amyloidosis, a complication that can damage the kidneys and other organs. This is a risk to prevent, not an inevitable outcome.
The EULAR/PReS FMF recommendations emphasize controlling attacks and inflammation between attacks. Daily colchicine remains the foundation of long-term prevention for most patients. When it is insufficient or poorly tolerated, the team should review adherence, side effects, interactions, and other explanations before adjusting treatment; IL-1-targeted medicines are options for selected patients. Do not increase or stop colchicine on your own.
Bring three questions to your next visit
- What does my specific genetic result mean in the context of my symptoms?
- How will we check for inflammation between attacks and monitor my kidneys?
- What is our plan if attacks continue or treatment causes side effects?
The goal is not simply to explain the genetic report. It is to help you feel well, preserve daily life, and prevent complications.
Keep reading
Sources and further reading
- EULAR/PReS FMF management recommendations: 2024 update, published 2025
- Jéru et al. The risk of FMF in MEFV heterozygotes (2013)
- Lachmann et al. Clinical and subclinical inflammation in FMF and MEFV carriers (2006)
Adapted from Jonathan S. Hausmann’s presentation, “More than genes: familial Mediterranean fever,” with references and terminology updated for this article. Individual patient cases and slide images have not been reproduced.
This article provides general education, not a diagnosis or an individual treatment plan. Discuss personal medical decisions with your care team.